Category Archives: pricing

Paying for the Future of Medicine

Is the hallmark of innovation higher drug prices? The three leading justifications for sticker-shocking drug prices in the US, from the biopharma perspective, are: 1) it costs a lot to bring a drug to market;* 2) drugs – even very expensive ones – are cheaper in the long run since they prevent complications, hospitalizations and […]
Also posted in Biotech, FDA, healthcare, leadership, Manufacturing, Market Access, R&D, Regulatory, Technology | Tagged , , , , , , | 1 Comment

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Also posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, Regulatory | Tagged , , , , , , , , | Leave a comment

Global Price Management Key to Boosting Margins

Global price management will lead the fight-back on margins, writes Arnaud Grunwald. Price erosion, falling sales and dwindling product pipelines — they are all inflicting pain on boardrooms in the pharma industry. What a gloomy outlook, you might think. But it is out of this dark cloud that global price management is emerging as a […]
Also posted in Strategy | Tagged , | Leave a comment

Eight Ingredients for a Successful Oncology Drug Development Recipe

by Matthew Cook and Sebastien Morisot In light of the risks and challenges inherent in the development of oncologics, some biopharma companies are beginning to question whether oncology remains an attractive therapeutic area in which to invest limited research, development, and commercialization resources.
Also posted in Agency Insight, Biotech, Europe, FDA, Gene therapy, Guest Blog, leadership, Market Access, Orphan Drugs, R&D, Regulatory, Sales | Tagged , , | Leave a comment

England: Ignoring NICE Guidelines Can Be Unlawful

By Leela Barham. An administrative court has said that a Clinical Commission Group (CCG, a local budget holder for the National Health Service in England) can’t just disagree with guidance from the UK’s National Institute for Health and Clinical Excellence (NICE) — that’s unlawful.
Also posted in Europe, Guest Blog, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta